Mentorship in Pulmonary Vascular Disease

肺血管疾病的指导

• 批准号: 10370102
• 负责人: Anna R Hemnes
• 金额: $ 11.46万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10370102
• 关键词: Affect; Award; Basic Science; Bioinformatics; Blood Vessels; Career Mobility; Cessation of life; Classification; Clinic; Clinical; Clinical Research; Clinical Trials; Data; Development; Diagnosis; Disease; Disease Marker; Educational workshop; Faculty; Funding; Goals; Grant; Guidelines; Human; Insulin Resistance; International; Intervention; Lead; Lipids; Lung; Lung diseases; Measures; Mentors; Mentorship; Metabolic; Metabolic Diseases; Metabolic dysfunction; Metformin; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; Molecular; National Heart, Lung, and Blood Institute; Outcome; Pathogenesis; Patients; Phenotype; Play; Postdoctoral Fellow; Predisposition; Program Research Project Grants; Prospective cohort; Publications; Pulmonary Hypertension; Recording of previous events; Research; Research Personnel; Research Project Grants; Research Training; Resources; Right Ventricular Dysfunction; Role; Scientist; Severity of illness; Techniques; Testing; Time; Training; United States; United States National Institutes of Health; Work; base; career; career development; clinical phenotype; cohort; effective therapy; experience; improved; large datasets; member; molecular phenotype; mortality; next generation; novel therapeutics; patient oriented; patient oriented research; precision medicine; programs; pulmonary arterial hypertension; pulmonary vascular disorder; recruit; resilience; response; right ventricular failure; skills; student mentoring; training opportunity; treatment response; treatment strategy; working group

Pulmonary arterial hypertension (PAH) is a rare lung disease characterized by progressive pulmonary vascular obliteration resulting in right ventricular failure and ultimately death. Throughout the last three decades there has been tremendous progress in understanding disease mechanisms that have led to new therapies, however survival remains poor at approximately 8 years after diagnosis for most patients. There have been several recent NIH/NHLBI sponsored workshops on phenotyping patients with PAH and moving accumulating “Omic” data into the clinic to advance precision medicine in PAH, yet there are few centers in where this work is ongoing and training the next generation of researchers in these techniques will be critically important to advancing the field of PAH therapy and pulmonary vascular disease more broadly. Dr. Hemnes is a well- recognized expert in this field and her objective is to use the support of the K24 Midcareer Investigator Award in Patient-Oriented Research to focus on training the next generation of scientists to bring precision medicine approaches to PAH patient therapy. The candidate’s immediate and long-term career objectives are directly in line with the goals of the NIH K24 award, to provide support for protected time for awardees to devote to patient-oriented research and culturally-sensitive mentoring for students, residents, fellows and junior faculty. Specifically, this award will allow her to focus on the development of (1) a patient-oriented research program in pulmonary vascular disease research and (2) a mentoring program to facilitate the career development of new investigators. This award will provide protected time for the candidate to devote specifically to developing mentoring skills in patient-oriented research. Her objective is to recruit and mentor students, residents, fellows and junior faculty for successful clinical research careers in pulmonary vascular disease and to support the career advancement of her current trainees who are fellows and junior faculty members. To expand her patient-oriented research program in PAH, she will combine two lines of study in her research portfolio (1) understanding how insulin resistance in the lipid axis may predispose to PAH or affect outcomes and (2) using Omic techniques to deep phenotype patients with pulmonary vascular disease. The proposal here will build on her funded work to test the hypothesis that Omic signatures in PAH can identify features of resilience to PAH progression and metabolic intervention susceptibility. The specific aims are (1) To compare PAH patients with and without Omic signatures of metabolic dysfunction, define differences in clinical and molecular features and measure relevant outcomes between the two groups, (2) To test and validate Omic predictors of metformin responses in completed and ongoing clinical trials in PAH patients. Completion of these aims will enhance understanding of the pathogenesis of PAH and uncover potentially improved treatment strategies of metabolic disease in PAH specifically. The proposed new research, along with the candidate’s other funded research projects, will provide invaluable training opportunities in patient-oriented pulmonary vascular disease research.

肺动脉高压（PAH）是一种罕见的肺部疾病，其特征是进行性肺血管病变 在过去的三十年中，心脏衰竭导致右心室衰竭并最终死亡。 然而，在理解疾病机制方面取得了巨大进展，从而催生了新疗法 大多数患者在诊断后约 8 年生存率仍然很低。 最近 NIH/NHLBI 主办了关于 PAH 患者表型分析和移动累积“Omic”的研讨会 将数据输入临床以推进肺动脉高压的精准医学，但开展这项工作的中心很少 持续进行并培训下一代研究人员使用这些技术对于 Hemnes 博士致力于更广泛地推进 PAH 治疗和肺血管疾病领域的发展。 该领域公认的专家，她的目标是利用 K24 职业中期研究员奖的支持 以患者为导向的研究重点是培训下一代科学家带来精准医学 PAH 患者的治疗方法直接关系到候选人的近期和长期职业目标。 符合 NIH K24 奖项的目标，为获奖者投入受保护的时间提供支持 为学生、住院医师、研究员和初级教员提供以患者为中心的研究和文化敏感的指导。 具体来说，该奖项将使她能够专注于开发（1）以患者为导向的研究项目 肺血管疾病研究和（2）促进新人职业发展的指导计划 该奖项将为候选人提供受保护的时间专门致力于发展。 她的目标是招募和指导学生、住院医师和研究员。 和初级教师在肺血管疾病方面取得成功的临床研究生涯并支持 她目前的学员（研究员和初级教员）的职业发展，以扩展她的能力。 以患者为中心的 PAH 研究项目，她将在她的研究组合中结合两个研究方向 (1) 了解脂质轴中的胰岛素抵抗如何导致 PAH 或影响结果，以及 (2) 使用 本文的建议将建立在对肺血管疾病患者进行深部表型分析的组学技术之上。 她资助的工作是为了检验 PAH 中的 Omic 特征可以识别 PAH 恢复特征的假设 进展和代谢干预敏感性的具体目的是（1）比较 PAH 患者与 在没有代谢功能障碍的组学特征的情况下，定义临床和分子特征的差异， 测量两组之间的相关结果，(2) 测试和验证二甲双胍的组学预测因子 已完成和正在进行的 PAH 患者临床试验的反应将增强这些目标的完成。 了解 PAH 的发病机制并发现潜在的改善代谢性治疗策略 拟议的新研究，以及候选人的其他资助研究。 项目，将为以患者为导向的肺血管疾病研究提供宝贵的培训机会。